You are here: Industry Insights > Eylea

News List

Bayer, Arogya Finance join hands for Eylea Easy Pay Program in India expresspharma
December 22, 2020
Eylea or Aflibercept solution is indicated for the treatment of diabetic macular oedema (DME) and wet age-related macular degeneration (Wet AMD).
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases europeanpharmaceuticalreview
October 30, 2020
Ocumension Therapeutics announced that the Company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology Co. Ltd., a wholly-owned subsidiary of Luye Pharma Group Ltd. to jointly develop OT-702 ...
Bayer gets DCGI nod for intravitreal aflibercept injection, Eylea to treat diabetic macular edema expresspharma
September 23, 2020
Intravitreal Aflibercept is administered via injection directly in the area of swelling in the eye.
Neovascularization inhibitor sales will near $7 bn in diabetic retinopathy market in 2029: GlobalData expresspharma
September 18, 2020
This increase is expected to be driven by the demonstrable efficacy of these products in reducing the rate of angiogenesis and sight loss in diseases such as DR, diabetic macular oedema and retinal vein occlusion.
Regeneron's Eylea snags pre-filled syringe approval as Novartis rival looms fiercepharma
August 14, 2019
Eye med Eylea has been a blockbuster sales force for Regeneron, but Novartis’ challenger brolucizumab is on the horizon. Could a new delivery option give Eylea a leg up?
FDA Approves EYLEA Injection Prefilled Syringe americanpharmaceuticalreview
August 14, 2019
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA® (aflibercept) Injection prefilled syringe.
Regeneron's Eylea pads its armor with diabetic retinopathy approval fiercepharma
May 15, 2019
With a major challenger on the fast track to approval in Novartis’ brolucizumab, Regeneron’s Eylea has been on the hunt for a new indication to boost its best-in-class sales.
Regeneron’s Eylea wins FDA approval pharmatimes
May 15, 2019
Regeneron has announced that its Eyela (aflibercept) injection has been approved by the US Food and Drug Administration (FDA) to treat all stages of diabetic retinopathy (DR), and thereby reduce the risk of blindness.
FDA expands indication for Eylea to cover all stages of diabetic retinopathy pharmafile
May 15, 2019
The FDA has expanded the indication for Regeneron’s Eylea (aflibercept) to include all stages of diabetic retinopathy.
Bayer's Q1 sales boosted by performance of Xarelto, Eylea, while profit held back by acquisition, restructuring costs firstwordpharma
April 26, 2019
CEO Werner Baumann noted that the pharmaceutical division "delivered encouraging performance."

Previous page 1 2 3 Next page